Horizon Therapeutics Plc (HZNP) - Comprehensive Stock Analysis & Investment Research
Deep dive into Horizon Therapeutics Plc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Understanding Company Overview
What this section covers: Essential business information about Horizon Therapeutics Plc, including sector classification, industry positioning, and organizational structure.
How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.
For Horizon Therapeutics Plc: Horizon Therapeutics Plc operates in the Manufacturing sector, positioning it as a large-cap market leader.
Horizon Therapeutics Plc (Stock Symbol: HZNP) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.
The organization employs approximately 1440 professionals worldwide and operates under the strategic leadership of CEO Timothy P Walbert.
The company has established itself as a major market leader with significant institutional backing.
Understanding Financial Performance
What these metrics mean: Key financial indicators showing Horizon Therapeutics Plc's revenue scale, profitability, market value, and shareholder returns.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Horizon Therapeutics Plc: With $280M in annual revenue and 158.5% net margin, the company demonstrates exceptional profitability.
Annual Revenue: $280 million generating a 158.5% net profit margin .
Market Capitalization: $26626 million - Classified as a large-cap stock with institutional-grade stability.
Return on Equity (ROE): 19.9% - Excellent shareholder return efficiency, indicating strong management effectiveness.
Understanding AI Stock Predictions
What these predictions mean: AI-powered forecasts for Horizon Therapeutics Plc stock using machine learning algorithms trained on historical market data and technical indicators.
How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.
For Horizon Therapeutics Plc: Unlock premium access to view detailed AI predictions and price targets.
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Horizon Therapeutics Plc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Understanding Market Position
What this analysis covers: Horizon Therapeutics Plc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.
How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.
For Horizon Therapeutics Plc: Strong free cash flow generation demonstrates exceptional operational efficiency.
Horizon Therapeutics Plc strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence .
The company demonstrates robust operational efficiency through strong free cash flow generation of $1108 million annually, complemented by impressive 30.3% year-over-year cash flow growth.
The company maintains a healthy 978.1% gross margin, indicating strong pricing power and operational efficiency.